Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs.

Abstract

OBJECTIVE:

To evaluate the antitumor and toxic effects of treatment with doxorubicin combined with piroxicam or doxorubicin alone for multicentric lymphoma in dogs.

DESIGN:

Nonrandomized clinical trial.

ANIMALS:

75 dogs with multicentric lymphoma.

PROCEDURE:

33 dogs were treated with doxorubicin (30 mg/m2, IV, q 21 d, for 3 doses) and piroxicam (0.3 mg/kg [0.14 mg/lb], PO, q 24 h); results were compared with a historical control group of 42 dogs treated with doxorubicin (30 mg/M2, IV, q 21 d, for 3 doses) alone. Results-The percentages of dogs that had remission with doxorubicin-piroxicam treatment (79%) or doxorubicin treatment alone (74%) were not significantly different. Median duration of first remission was 130 days with doxorubicin-piroxicam and 147 days with doxorubicin alone; these values were not significantly different. Severe toxicosis was observed in 22% of dogs treated with doxorubicin-piroxicam and 17% of dogs treated with doxorubicin alone.

CONCLUSIONS AND CLINICAL RELEVANCE:

Both treatment protocols were efficacious and well tolerated. The doxorubicin-piroxicam treatment was no more effective regarding response rate, remission duration, or survival duration, compared with the control group treated with doxorubicin alone.

• Authors: Anthony J Mutsaers, Nita W Glickman, Dennis B DeNicola, William R Widmer, Patty L Bonney, Kevin A Hahn, Deborah W Knapp
• Journal: Journal of the American Veterinary Medical Association (J Am Vet Med Assoc) Vol. 220 Issue 12 Pg. 1813-7 (Jun 15 2002) ISSN: 0003-1488 [Print] United States
• PMID: 12092954 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Antineoplastic Agents
• Piroxicam
• Doxorubicin

Topics

• Animals
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Dog Diseases (drug therapy)
• Dogs
• Doxorubicin (administration & dosage, adverse effects, therapeutic use)
• Female
• Lymphoma (drug therapy, veterinary)
• Male
• Piroxicam (administration & dosage, adverse effects, therapeutic use)
• Remission Induction
• Survival Analysis
• Treatment Outcome